{"id":32471,"date":"2021-04-20T10:35:33","date_gmt":"2021-04-20T10:35:33","guid":{"rendered":"https:\/\/www.etap-lab.com\/?p=12471"},"modified":"2026-04-17T17:50:24","modified_gmt":"2026-04-17T15:50:24","slug":"alzheimers-disease-a-new-preclinical-model-drugdiscovery","status":"publish","type":"post","link":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/","title":{"rendered":"Alzheimer\u2019s Disease \u2013 a new preclinical model #2"},"content":{"rendered":"\n<p>Intracerebral administration of AB<sub>1-42<\/sub> (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in aged mice.<\/p>\n\n\n\n<p>As announced a few weeks ago, we evaluated the effects of A\u03b2O on synaptic function and cell survival. Quantification of protein expression in the hippocampus 18 days after intracerebral administration showed disruption to synaptic function (PSD-95) and apoptotic signalling in brain tissue.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter wp-image-12472\"><img decoding=\"async\" src=\"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg\" alt=\"Figure 1: Graphical representation of PSD-95 expression and Bax\/Bcl-2 ratio in the hippocampus, 18 days after A\u03b2O administration.\" class=\"wp-image-12472\"\/><figcaption class=\"wp-element-caption\"><strong>Figure 1: Graphical representation of PSD-95 expression and Bax\/Bcl-2 ratio in the hippocampus, 18 days after A\u03b2O administration.<\/strong><\/figcaption><\/figure>\n\n\n\n<p><span style=\"font-size: 16px;\">The results obtained during our R&amp;D project allowed us to develop a new model of early-stage Alzheimer&#8217;s disease, based on A\u03b2O toxicity. Thanks to ETAP-Lab&#8217;s unique expertise, this toxicity has been demonstrated in vitro (in primary neuronal cultures) and in vivo (in aged mice). A\u03b2O causes increased neuronal death in vitro, and cognitive impairment and biological changes that are characteristic of AD in vivo. The effects induced by A\u03b2O are sensitive to reference molecules, reducing cell death in vitro and improving cognitive performance in vivo.<\/span><\/p>\n\n\n\n<p>The A\u03b2O and associated models ETAP-Lab now offer make it possible to evaluate &#8211; with strong scientific added value &#8211; the efficacy and therapeutic potential of molecules against Alzheimer&#8217;s disease, both in vitro and in vivo.<\/p>\n\n\n\n<p>Please <a href=\"https:\/\/www.etap-lab.com\/contact-us\/\">contact our team of specialists<\/a> for more information on this new model.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-container-core-buttons-is-layout-a89b3969 wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/www.etap-lab.com\/contact-us\/\">Contact us<\/a><\/div>\n<\/div>\n\n\n\n<p>&nbsp;<\/p>\n\n\n\n<p>This research was carried out as part of the Bioprolor2 programme. Bioprolor2 is co-financed by the \u201cRegion Grand-Est\u201d and the European Union through the \u201cFEDER-FSE Lorraine et Massif des Vosges 2014-2020\u201d operational programme.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[205],"tags":[],"aire-therapeutique":[],"class_list":["post-32471","post","type-post","status-publish","format-standard","hentry","category-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alzheimer\u2019s Disease \u2013 a new preclinical model #2 - ETAP-LAB<\/title>\n<meta name=\"description\" content=\"Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzheimer\u2019s Disease \u2013 a new preclinical model #2 - ETAP-LAB\" \/>\n<meta property=\"og:description\" content=\"Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/\" \/>\n<meta property=\"og:site_name\" content=\"ETAP-LAB\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-20T10:35:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-17T15:50:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg\" \/>\n<meta name=\"author\" content=\"Ana\u00efs GAVOILLE\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana\u00efs GAVOILLE\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/\"},\"author\":{\"name\":\"Ana\u00efs GAVOILLE\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/person\\\/5795847a84eb95e1faecaac7eaf85ba9\"},\"headline\":\"Alzheimer\u2019s Disease \u2013 a new preclinical model #2\",\"datePublished\":\"2021-04-20T10:35:33+00:00\",\"dateModified\":\"2026-04-17T15:50:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/\"},\"wordCount\":267,\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg\",\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/\",\"name\":\"Alzheimer\u2019s Disease \u2013 a new preclinical model #2 - ETAP-LAB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg\",\"datePublished\":\"2021-04-20T10:35:33+00:00\",\"dateModified\":\"2026-04-17T15:50:24+00:00\",\"description\":\"Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Company\",\"item\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/corporate\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Alzheimer\u2019s Disease \u2013 a new preclinical model #2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"name\":\"Etap Lab\",\"description\":\"CRO Services\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#organization\",\"name\":\"Etap Lab\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"contentUrl\":\"https:\\\/\\\/www.etap-lab.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png\",\"width\":550,\"height\":550,\"caption\":\"Etap Lab\"},\"image\":{\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/etap-lab\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.etap-lab.com\\\/en\\\/#\\\/schema\\\/person\\\/5795847a84eb95e1faecaac7eaf85ba9\",\"name\":\"Ana\u00efs GAVOILLE\",\"description\":\"Marketing expert at ETAP-LAB.\",\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/anais-gavoille-54lorraine\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzheimer\u2019s Disease \u2013 a new preclinical model #2 - ETAP-LAB","description":"Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/","og_locale":"en_US","og_type":"article","og_title":"Alzheimer\u2019s Disease \u2013 a new preclinical model #2 - ETAP-LAB","og_description":"Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026","og_url":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/","og_site_name":"ETAP-LAB","article_published_time":"2021-04-20T10:35:33+00:00","article_modified_time":"2026-04-17T15:50:24+00:00","og_image":[{"url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg","type":"","width":"","height":""}],"author":"Ana\u00efs GAVOILLE","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ana\u00efs GAVOILLE","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#article","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/"},"author":{"name":"Ana\u00efs GAVOILLE","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/person\/5795847a84eb95e1faecaac7eaf85ba9"},"headline":"Alzheimer\u2019s Disease \u2013 a new preclinical model #2","datePublished":"2021-04-20T10:35:33+00:00","dateModified":"2026-04-17T15:50:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/"},"wordCount":267,"publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#primaryimage"},"thumbnailUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg","articleSection":["Company"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/","url":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/","name":"Alzheimer\u2019s Disease \u2013 a new preclinical model #2 - ETAP-LAB","isPartOf":{"@id":"https:\/\/www.etap-lab.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#primaryimage"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#primaryimage"},"thumbnailUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg","datePublished":"2021-04-20T10:35:33+00:00","dateModified":"2026-04-17T15:50:24+00:00","description":"Discover Alzheimer\u2019s Disease \u2013 a new preclinical model #2: Intracerebral administration of AB 1-42 (A\u03b2O) oligomers disrupts synaptic function and increases cell death in brain tissue in\u2026","breadcrumb":{"@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#primaryimage","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2020\/12\/Figure-1-Graphc-A-beta-oligomers-PSD-95-Bax-Bcl2-.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.etap-lab.com\/en\/corporate\/alzheimers-disease-a-new-preclinical-model-drugdiscovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.etap-lab.com\/en\/"},{"@type":"ListItem","position":2,"name":"Company","item":"https:\/\/www.etap-lab.com\/en\/corporate\/"},{"@type":"ListItem","position":3,"name":"Alzheimer\u2019s Disease \u2013 a new preclinical model #2"}]},{"@type":"WebSite","@id":"https:\/\/www.etap-lab.com\/en\/#website","url":"https:\/\/www.etap-lab.com\/en\/","name":"Etap Lab","description":"CRO Services","publisher":{"@id":"https:\/\/www.etap-lab.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.etap-lab.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.etap-lab.com\/en\/#organization","name":"Etap Lab","url":"https:\/\/www.etap-lab.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","contentUrl":"https:\/\/www.etap-lab.com\/wp-content\/uploads\/2026\/03\/etap-lab-etap-lab-preclinical-cro-right-full-color-rgb-1920px-w-72ppi.png","width":550,"height":550,"caption":"Etap Lab"},"image":{"@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/etap-lab\/"]},{"@type":"Person","@id":"https:\/\/www.etap-lab.com\/en\/#\/schema\/person\/5795847a84eb95e1faecaac7eaf85ba9","name":"Ana\u00efs GAVOILLE","description":"Marketing expert at ETAP-LAB.","sameAs":["https:\/\/www.linkedin.com\/in\/anais-gavoille-54lorraine\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/posts\/32471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/comments?post=32471"}],"version-history":[{"count":0,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/posts\/32471\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/media?parent=32471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/categories?post=32471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/tags?post=32471"},{"taxonomy":"aire-therapeutique","embeddable":true,"href":"https:\/\/www.etap-lab.com\/en\/wp-json\/wp\/v2\/aire-therapeutique?post=32471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}